International Journal of Scientific Trends- (IJST)
ISSN: 2980-4299
Volume 3, Issue 12, December - 2024
Website: https://scientifictrends.org/index.php/ijst
Open Access, Peer Reviewed, Scientific Journal

Psychological and Biological Changes Observed in The Mind of Patients with Alzheimer's Disease

Narmetova Yulduzxan Karimovna
Assistant Teacher of Tashkent Medical Academy,
Department of Psychology and Pedagogics

Abdizhamilova Zerzada Abdisalamovna
Student, Tashkent Medical Academy

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and significant psychological changes, making it one of the most common causes of dementia in older adults. Affecting millions worldwide, AD poses a profound impact on both patients and their families. This paper explores the dual dimensions of Alzheimer's disease: the biological changes in the brain and the psychological alterations experienced by patients. Biologically, AD is marked by the buildup of amyloid-beta plaques and tau protein tangles, leading to neuronal death and brain atrophy, particularly in regions responsible for memory and executive functions. These structural changes in the brain correlate with a gradual decline in mental faculties, manifested in memory loss, impaired judgment, and disorientation.

Psychologically, Alzheimer's patients undergo emotional and behavioral shifts that can include depression, anxiety, agitation, and hallucinations, affecting their overall quality of life and social relationships. These psychological changes often exacerbate as the disease progresses, transforming not only the patient's cognitive state but also their personality and emotional well-being. Research has shown that biological changes in the brain contribute directly to these psychological symptoms, revealing a complex interplay between molecular and psychological processes. Advances in neuroimaging and biomarker studies have improved the understanding of AD pathology, yet effective treatments remain limited.

This paper aims to shed light on the intricate relationship between the psychological and biological aspects of Alzheimer's disease, reviewing current scientific understanding and exploring potential pathways for future research. By deepening our insight into the mechanisms underlying these changes, we may move closer to

International Journal of Scientific Trends- (IJST)
ISSN: 2980-4299
Volume 3, Issue 12, December - 2024
Website: https://scientifictrends.org/index.php/ijst
Open Access, Peer Reviewed, Scientific Journal

	developing interventions that can mitigate the cognitive and psychological decline associated with this devastating disease.

Keywords: Neurodegeneration, amyloid plaques, cognitive decline, brain atrophy, behavioral changes, dementia, biomarkers, emotional changes.

Introduction

Alzheimer's disease is the most common cause of dementia. Alzheimer's disease is the biological process that begins with the appearance of a buildup of proteins in the form of amyloid plaques and neurofibrillary tangles in the brain. This causes brain cells to die over time and the brain to shrink. About 6.9 million people in the United States age 65 and older live with Alzheimer's disease. Among them, more than 70% are age 75 and older. Of the more than 55 million people in the world with dementia, 60% to 70% are estimated to have Alzheimer's disease.

Early symptoms of Alzheimer's disease include forgetting recent events or conversations. Over time, Alzheimer's disease leads to serious memory loss and affects a person's ability to do everyday tasks.

MATERIALS AND METHODS:

Brain Function and Structure:

The healthy human brain contains tens of billions of neurons, which are specialized cells that process and transmit information via electrical and chemical signals. These cells send messages between different parts of the brain, and from the brain to the muscles and organs of the body. Alzheimer’s disease disrupts this communication, resulting in widespread loss of brain function as many neurons stop working properly and eventually die.

How does Alzheimer’s affect the brain?

The brain typically shrinks to some degree in healthy aging, but surprisingly, does not lose neurons in large numbers. In Alzheimer’s, however, damage is widespread, as many neurons stop functioning properly, lose connections with other neurons, and eventually die. Alzheimer’s disrupts processes vital to neurons and their networks, including communication, metabolism, and repair.

At first, Alzheimer’s usually damages the connections among neurons in parts of the brain involved in memory, including the entorhinal cortex and hippocampus. It later affects areas in the cerebral cortex responsible for language, reasoning, and social behavior. Eventually, many other areas of the brain and surrounding neurons are damaged and stop working normally. Over time, a person with Alzheimer’s gradually loses their ability to live and function independently. Ultimately, the disease is fatal.

What are the main characteristics of the brain with Alzheimer’s?

Before the early 2000s, the only sure way to know whether a person had Alzheimer’s or another type of dementia was by viewing molecular and cellular changes in brain tissue under a microscope after death. Thanks to advances in research, diagnostics including brain PET scan imaging and blood tests are now available to help doctors and researchers detect biomarkers

associated with dementia in a living person, enabling more precise and earlier diagnoses. Investigations are underway to determine which changes may cause Alzheimer's and which may be a result of the disease

Amyloid Plaques

In Alzheimer's disease, beta-amyloid protein is produced from the breakdown of a larger protein known as amyloid precursor protein (APP). This protein exists in several molecular forms that accumulate between neurons, with the beta-amyloid 42 form being particularly harmful. In an Alzheimer's-affected brain, abnormal amounts of beta-amyloid clump together, forming plaques that interfere with cell function.

Current research is focusing on understanding how different forms of beta-amyloid contribute to Alzheimer's and at what stages they become influential. Drugs targeting beta-amyloid are being investigated as potential treatments. The U.S. Food and Drug Administration (FDA) has granted full approval to two anti-amyloid drugs, lecanemab and donanemab, for use in early-stage Alzheimer's. These medications reduce amyloid plaques, and studies indicate they may slow cognitive decline associated with Alzheimer's in some individuals. Learn more about these drugs, along with other medications and treatment options for Alzheimer's disease.

Chronic inflammation

Research suggests that chronic inflammation may be caused by the buildup and harmful secretions of malfunctioning glial cells. Healthy glial cells help keep the brain free of debris. A type of glial cell called microglia engulfs and destroys waste and toxins in a healthy brain. When microglia fail to clear away waste, debris, and protein collections, including beta-amyloid plaques, Alzheimer's can develop. Researchers are trying to discover the mechanisms of how and why microglia malfunction.

One study is focusing on a protein called TREM2, which is essential for proper microglial function during stress events, including neurodegenerative diseases. When TREM2 does not function normally, plaques build up between neurons. Astrocytes — another type of glial cell — are signaled to help clear the buildup of plaques and other cellular debris. Faulty microglia and astrocytes then collect around the neurons but don't perform their debris-clearing function. They can release chemicals that cause chronic inflammation and further damage the neurons they are meant to protect.

Neuroimaging Techniques

• Magnetic Resonance Imaging (MRI): Used to detect brain atrophy and structural changes in brain regions affected by Alzheimer's, particularly the hippocampus and cortex.

• Positron Emission Tomography (PET): Utilized with amyloid and tau tracers to visualize amyloid plaques and tau neurofibrillary tangles, hallmark signs of Alzheimer's pathology. PET scans can also show patterns related to neurodegeneration and track disease progression.

• Functional MRI (fMRI): Applied to study functional changes and connectivity in brain networks related to cognitive decline, as well as changes in brain activity during memory or other cognitive tasks.

Biochemical Assays and Biomarkers

• Cerebrospinal Fluid (CSF) Analysis: Lumbar puncture samples are analyzed to measure biomarkers like amyloid-beta and phosphorylated tau proteins, which correlate with neurodegeneration and cognitive decline.

• Blood-Based Biomarkers: Less invasive blood tests are being developed to measure amyloid and tau, as well as other markers like neurofilament light chain (NfL) and inflammatory markers, which may indicate brain atrophy and cellular damage.

• Genetic Testing: Testing for genetic risk factors, such as the APOE ε4 allele, can help identify individuals with a higher predisposition for Alzheimer's and may provide insights into the underlying genetic components of dementia and neurodegeneration.

Neuropsychological Assessments

• Cognitive Testing: Tools such as the Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) are standard for measuring cognitive decline and memory impairment. These tests evaluate areas like memory, language, executive function, and orientation.

• Behavioral and Emotional Assessment: Tools like the Neuropsychiatric Inventory (NPI) help assess behavioral changes and emotional symptoms such as agitation, depression, anxiety, and hallucinations. Such symptoms are essential for understanding behavioral changes and emotional changes in Alzheimer's disease.

Postmortem Histological Analysis

• Brain Tissue Analysis: Postmortem studies allow researchers to examine amyloid plaques and tau tangles directly within brain tissue using histological staining techniques. These analyses provide a detailed look at neurodegeneration and validate findings from biomarkers and imaging.

• Immunohistochemistry: This technique is used to visualize specific proteins in brain tissue, such as amyloid-beta and tau, providing insights into the distribution and density of pathological markers.

Behavioral and Psychological Observations in Patients

• Clinical Observations: Regular observations of patients by healthcare providers allow for tracking behavioral changes over time, which could include changes in social behavior, daily routines, and personality.

• Self-Reported and Caregiver-Reported Questionnaires: Gathering data from caregivers and patients using tools like the Alzheimer's Disease Cooperative Study Activities of Daily Living (ADCS-ADL) inventory provides insight into how dementia affects the quality of life and behavior, offering a fuller picture of cognitive and emotional changes.

Experimental or Animal Models

Transgenic Animal Models: Using mouse models genetically engineered to overexpress human amyloid-beta or tau proteins allows researchers to study the development of amyloid plaques, neurodegeneration, and cognitive decline in controlled settings. Observing behaviors like memory tasks and emotional reactions in these models can provide insights relevant to human behavioral changes.

CONCLUSION

Alzheimer's disease remains a complex and challenging neurodegenerative disorder, marked by both biological and psychological changes that profoundly impact patients and their families. The presence of amyloid plaques, tau protein tangles, and brain atrophy provide clear biological markers of the disease, while cognitive decline, behavioral shifts, and emotional disturbances highlight its psychological impact. Together, these changes contribute to the progressive loss of memory, personality, and independence in those affected.

Despite advances in our understanding of Alzheimer's pathology, effective treatments remain limited. However, recent developments in drugs targeting amyloid plaques, such as lecanemab and donanemab, show promise in slowing cognitive decline in some patients. Continued research into the molecular mechanisms, biomarkers, and neuroimaging techniques is essential to developing earlier diagnostic tools and more effective therapies.

References

1.CR Jack, VJ Lowe, SD Weigand, HJ Wiste, ML Senjem, DS Knopman, et al. Serial PiB and MRI in normal, mild cognitive impairment and Alzheimer's disease: Implications for sequence of pathological events in Alzheimer's disease. Brain. 132: 2009; 1355–1365

2. National Institutes of Health. National Institute on Aging. What happens to the Brain in Alzheimer's Disease?, Available at: https://www.nia.nih.gov/health/what-happens-brainalzheimers-disease Accessed September 14, 2018

3. Mayo Clinic. Alzheimer's disease – causes and symptoms. Available at: https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447

4. RA Sperling, PS Aisen, LA Beckett, DA Bennett, S Craft, AM Fagan, et al. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7: 2011; 280–292

5. R. Katzman. The prevalence and malignancy of Alzheimer disease: A major killer. Arch Neurol (1976)

6. W.W. Barker et al. Relative frequencies of Alzheimer's disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord(2002)

7. Karimovna, N. Y. (2022). Autism and the importance of communication with patients of this disease. *Gospodarka i Innowacje.*, *23*, 8-10.

8. Нарметова, Ю. (2015). Методологические и методические проблемы организации психологической службы в медицинских учреждениях.

9. Narmetova, Y. (2024). COMPARATIVE ANALYSIS OF THE PSYCHOLOGICAL STATE AND SOCIO-PSYCHOLOGICAL CHARACTERISTICS OF PATIENTS WITH PSYCHOSOMATIC DISEASES. *Current approaches and new research in modern sciences*, *3*(3), 83-87.

10. Karimovna, N. Y., Nasirovna, M. R., Tursunaliyevna, A. M., Abduvaliyevna, A. N., & Ravshanovna, U. S. (2023). Psychodiagnostics of psychosomatic diseases. *Journal of survey in fisheries sciences*, *10*(2S), 2903-2911.

11. Karimovna, N. Y., Khasanboy, A., Iltifotkhon, A., Khabiba, N., & Adiba, M. (2023). Psychoemotional characteristics in psychosomatic diseases. *The Scientific Temper*, *14*(04), 1444-1450.